Newsbenzinga
FDA Conditionally Approves AstraZeneca's Rare Kidney Disease Drug
· Published
Article summary
FDA grants accelerated approval to AstraZeneca's Ultomiris for adult IgAN to lower proteinuria, pending data on long-term kidney benefit.
An excerpt from the original article.
Comments —
Loading comments…